HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First tuberculosis vaccine trial years begins

(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, the ... to lead a national chief operating officer recruitment for Nicklaus Children’s ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/2/2015)... ... ... AvePoint Public Sector, Inc., a wholly owned subsidiary of ... it was named the recipient of the 2015 GTRA ConVurge Tech Award for Excellence ... Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge Honorary Awards ...
(Date:7/2/2015)... ... July 02, 2015 , ... As the world becomes more connected through ... they interact with products in their everyday lives. Technology can now help homeowners gain ... home entertainment and safety, as well as making kitchen tasks simpler. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... A Board ... CoolSculpting Plus, an advanced approach to body contouring. CoolSculpting Plus combines CoolSculpting® ... About the basic CoolSculpting procedure:, The CoolSculpting procedure is the only ...
(Date:7/2/2015)... ... July 02, 2015 , ... Denver-based SlimGenics Weight Control ... was named No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz ... been recognized. The award identifies outstanding woman-owned businesses that demonstrate excellence and success ...
Breaking Medicine News(10 mins):Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 2Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 3Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 4Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3
(Date:7/2/2015)... Conn. , July 2, 2015 Numotion,s ... Executive Officer announced that Tamas Feitel has ... Feitel joins Numotion after a highly successful 18 year ... leadership roles driving strategy, profitability, and productivity to result ... most recent position was Chief Financial Officer for GE ...
(Date:7/2/2015)... , July 2, 2015   Decision Resources ... retinal specialists identify less frequent dosing as the ... due to the burden on both patients and ... growth factor (VEGF) injections, which are the current ... abicipar pegol, which is in development for dosing ...
(Date:7/2/2015)... The report "Silage Inoculants & Enzymes Market ... Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & Geography - ... Enzymes Market is expected to reach $489.05 Million by ... 2020. Browse 75 market Tables and ... P ages and an in-depth TOC on ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
Cached News: